Restrictions on Business Activities and Sluggish Demand Due to the Spread of COVID-19
First written in FY2021-Q1. 11 of 13 entries say "Reframed", first in FY2021-Q2. Latest entry: FY2024-Q2.
Gun Ei Chemical Industry moved to the "Worse" side of this theme in 2021, 1 year after the typical company in this theme (2020).
The whole theme swung hardest in 2025: 5 of 16 companies on the "Worse" side.
15 other companies' latest entry also says "Restated".
- FY2024-Q2RestatedAnnual report
「In Japan, COVID-19 was reclassified under the Infectious Diseases Control Law as a Category V disease. Although the economy is on a gradual recovery track supported by an increase in visitors to Japan and firm personal consumption, the outlook is expected to remain uncertain as the country enters a phase of excess-inventory adjustment due to rising consumer prices caused by the substantially weaker yen and persistently high resource prices, as well as weaker external demand.」
The disclosure describes the easing of restrictions on business activity due to infectious diseases and the recovery of economic activity, while continuing to cite uncertainty factors such as the weaker yen, higher resource prices, and excess-inventory adjustments resulting from weaker external demand. - FY2024-Q1ReframedAnnual report
「In Japan, COVID-19 was reclassified under the Infectious Diseases Control Law as a Category V disease. Although the economy is on a gradual recovery track supported by firm personal consumption, the outlook is expected to remain uncertain as the country enters a phase of caution over rising consumer prices caused by the substantially weaker yen and persistently high resource prices, as well as excess inventories resulting from weaker external demand.」
Regarding COVID-19, the disclosure has shifted from its previous focus on restrictions on business activity and renewed spread of infections to describing the recovery of economic activity following the Category V reclassification and support from personal consumption. It also states that uncertainty remains due to the weaker yen, higher resource prices, and weaker external demand. - FY2023ReframedAnnual report
「・Suspension of operations and reduced production due to employees contracting an infectious disease ・Delays in the delivery of raw materials and shipment of products ・Formulation and timely review of BCP and BCM plans」
Infectious-disease risk has been organized as a business continuity risk, shifting from a focus on weak economic activity and demand to include employee infections, suspended operations, and delays involving raw materials and products. - FY2023-Q3ReframedAnnual report
「In Japan, economic and social activity and measures to control COVID-19 progressed in tandem, and the economy was on a gradual recovery track. However, conditions remained difficult due to the rapid depreciation of the yen, higher resource prices and consumer prices, and shortages of parts and semiconductors caused by global supply-chain disruptions. The outlook remains uncertain due to concerns about an economic slowdown resulting from anti-inflation measures in various countries, as well as geopolitical risks.」
The disclosure has shifted from its previous focus on restrictions on business activity due to infectious diseases to describing a recovery trend resulting from the parallel pursuit of infection control and economic activity, while also citing the weaker yen, higher resource prices and consumer prices, supply-chain disruptions, shortages of parts and semiconductors, anti-inflation measures, and geopolitical risks. - FY2023-Q2ReframedAnnual report
「In Japan, economic and social activity was moving toward normalization as vaccinations and other measures against COVID-19 progressed, but conditions remained difficult due to a rapid depreciation of the yen against the dollar, further increases in resource prices and consumer prices, and the rapid spread of a new variant in the seventh wave. The outlook is also expected to remain uncertain due to the renewed spread of COVID-19 variants and geopolitical risks.」
Regarding the effects of infectious diseases, the disclosure cites the normalization of economic and social activity through vaccinations alongside the seventh wave, new variants, the rapid depreciation of the yen against the dollar, higher resource prices and consumer prices, and geopolitical risks. - FY2023-Q1ReframedAnnual report
「In Japan, as economic and social activity moved toward normalization with progress in vaccinations and other measures against COVID-19, consumer prices rose due to a substantial decline in the yen's value and further increases in resource prices. The outlook is also expected to remain uncertain due to the renewed spread of COVID-19 variants and geopolitical risks.」
The disclosure has been updated from its previous focus on restrictions on economic activity due to infectious diseases to reflect progress toward normalization through vaccinations, while also citing uncertainty involving the renewed spread of variants and geopolitical risks. - FY2022-Q3ReframedAnnual report
「Looking ahead, economic activity is expected to recover as a result of measures to contain the spread of highly infectious variants, but conditions are expected to remain uncertain, with concerns including accelerating inflation due to persistently high crude oil prices and prolonged tightness in global supply and demand for commodities.」
Regarding infectious-disease risk, the disclosure describes both expectations of recovery resulting from infection-control measures against the spread of variants and uncertainty over the outlook due to the spread of infections, higher crude oil prices, and tight supply and demand for commodities. - FY2022-Q2ReframedAnnual report
「During the cumulative second quarter of the fiscal year, the global economy showed signs of recovery due to the effectiveness of measures taken by countries to prevent the spread of COVID-19 and the normalization of economic activity in the United States and China. However, it remained in a difficult situation from July onward due to the renewed spread of infections caused by variants. Although a recovery in economic activity is expected as the spread of infection is contained through measures such as vaccination, the outlook remains uncertain.」
Regarding the impact of infectious diseases, the disclosure describes both the recovery trend resulting from the normalization of economic activity and the continued difficult situation caused by renewed spread due to variants. - FY2022-Q1ReframedAnnual report
「During the cumulative first quarter of the fiscal year, the global economy was affected by the COVID-19 pandemic, but economic policies and measures to prevent the spread of infection were implemented in various countries, and economic activity began to normalize, particularly in the United States and China as vaccinations progressed. The economy was therefore on a recovery track in the near term. However, the outlook is expected to remain uncertain due to downside risks, including the renewed spread of infection resulting from an increase in COVID-19 variants.」
Regarding the effects of infectious diseases on economic activity and demand, the disclosure describes the current recovery trend while newly specifying renewed spread caused by variants and downside risks. - FY2021ReframedAnnual report
「Spread of infectious diseases ・Suspension of operations and reduced production due to employees contracting an infectious disease ・Delays in the delivery of raw materials and shipment of products ・Formulation and timely review of BCP and BCM plans」
In addition to the effects of COVID-19 on economic activity and demand, the company has identified general infectious-disease risks, including suspended operations and delays in raw-material deliveries and product shipments, and has specified countermeasures such as BCP and BCM. - FY2021-Q3ReframedAnnual report
「During the third quarter of the current consolidated cumulative period, the Japanese economy remained in a difficult situation as the global spread of COVID-19 caused economic activity to stagnate and personal consumption to weaken. Although the economy began to recover as economic activity resumed, infections have recently been spreading again, and the outlook remains uncertain.」
The disclosure describes a recovery resulting from the resumption of economic activity, while adding the recent resurgence of infections and uncertainty over the outlook, changing the description of infectious-disease risk from a situation that includes recovery to an uncertain situation accompanied by renewed spread. - FY2021-Q2ReframedAnnual report
「During the second quarter of the current consolidated cumulative period, the Japanese economy deteriorated rapidly as the global spread of COVID-19 caused economic activity to stagnate and personal consumption to weaken. Although economic activity gradually resumed and began to recover after the state of emergency was lifted, the outlook remained uncertain.」
While the stagnation of economic activity and weakness in personal consumption caused by COVID-19 continued, the disclosure also described the resumption and recovery of economic activity after the state of emergency was lifted, changing the risk description from rapid deterioration to an uncertain outlook that includes recovery. - FY2021-Q1First statedAnnual report
「During the first quarter of the current consolidated cumulative period, the Japanese economy deteriorated rapidly as the global spread of COVID-19 caused economic activity to stagnate and personal consumption to weaken. There are also concerns that the future spread of the infection in Japan and overseas may be prolonged, leaving the outlook extremely uncertain. Against this backdrop, the Group's business activities were restricted by the spread of COVID-19,」
The global spread of COVID-19 has caused economic activity and personal consumption to weaken and business activity to be restricted. Revenue decreased 6.2% year on year, operating profit decreased 16.3%, ordinary profit decreased 12.9%, and net profit attributable to owners of the parent decreased 13.0%, with specific effects also emerging in the Chemicals and Food businesses.